Astellas And MSD Agree To Co-Promote Ipragliflozin In Japan
This article was originally published in PharmAsia News
Executive Summary
Astellas and MSD signed an agreement on Sept. 2 for the co-promotion of the novel oral SGLT2 inhibitor ipragliflozin for hypoglycemia currently awaiting approval in Japan, the two companies announced.